Search

Your search keyword '"Sutedja, Tom G."' showing total 139 results
Start Over Author "Sutedja, Tom G." Publication Year Range Last 50 years
139 results on '"Sutedja, Tom G."'

2. Low Prevalence of High-Grade Lesions Detected With Autofluorescence Bronchoscopy in the Setting of Lung Cancer Screening in the Pan-Canadian Lung Cancer Screening Study

Author

Tremblay, Alain, Taghizadeh, Niloofar, McWilliams, Annette M., MacEachern, Paul, Stather, David R., Soghrati, Kam, Puksa, Serge, Goffin, John R., Yasufuku, Kazuhiro, Amjadi, Kayvan, Nicholas, Garth, Martel, Simon, Laberge, Francis, Johnston, Michael, Shepherd, Frances A., Ionescu, Diana N., Urbanski, Stefan, Hwang, David, Cutz, Jean-Claude, Sekhon, Harmanjatinder S., Couture, Christian, Xu, Zhaolin, Sutedja, Tom G., Atkar-Khattra, Sukhinder, Tammemagi, Martin C., Tsao, Ming-Sound, and Lam, Stephen C.

Published
2016
Full Text
View/download PDF

3. Photodynamic Therapy

Author

Sutedja, Tom G., Brady, L. W., editor, Heilmann, H.-P., editor, Molls, M., editor, and Jeremić, Branislav, editor

Published
2005
Full Text
View/download PDF

22. Exhaled breath analysis for lung cancer

Author

Dent, Annette G., Sutedja, Tom G., and Zimmerman, Paul V.

Subjects
Review Article, respiratory tract diseases
Abstract

Early diagnosis of lung cancer results in improved survival compared to diagnosis with more advanced disease. Early disease is not reliably indicated by symptoms. Because investigations such as bronchoscopy and needle biopsy have associated risks and substantial costs, they are not suitable for population screening. Hence new easily applicable tests, which can be used to screen individuals at risk, are required. Biomarker testing in exhaled breath samples is a simple, relatively inexpensive, non-invasive approach. Exhaled breath contains volatile and non-volatile organic compounds produced as end-products of metabolic processes and the composition of such compounds varies between healthy subjects and subjects with lung cancer. Many studies have analysed the patterns of these compounds in exhaled breath. In addition studies have also reported that the exhaled breath condensate (EBC) can reveal gene mutations or DNA abnormalities in patients with lung cancer. This review has summarised the scientific evidence demonstrating that lung cancer has distinct chemical profiles in exhaled breath and characteristic genetic changes in EBC. It is not yet possible to accurately identify individuals with lung cancer in at risk populations by any of these techniques. However, analysis of both volatile organic compounds in exhaled breath and of EBC have great potential to become clinically useful diagnostic and screening tools for early stage lung cancer detection.

Published
2013

24. BRONCHOSCOPIC THERAPY IS MORE COST-EFFECTIVE THAN SURGERY IN PATIENTS WITH INTRALUMINAL TYPICAL BRONCHIAL CARCINOID

Author

Codrington, Henk E., Postmus, Pieter E., and Sutedja, Tom G.

Subjects
Medical care, Cost of -- Analysis, Lung cancer -- Care and treatment, Health, Care and treatment, Analysis
Abstract

Henk E Codrington, MD(*) ; Pieter E Postmus, MD, PhD, FCCP and Tom G Sutedja, MD, PhD, FCCP. Dept. of Pulmonology, Academic Hospital Free University, Amsterdam , The Netherlands. PURPOSE: [...]

Published
2000

25. Cost-effectiveness of early intervention:comparison between intraluminal bronchoscopic treatment and surgical resection for T1N0 lung cancer patients

Author

Pasic, Arifa, Brokx, Hes A P, Vonk Noordegraaf, Anton, Paul, Rick M A, Postmus, Pieter E, Sutedja, Tom G, and Pulmonary medicine

Abstract

BACKGROUND: For patients with early-stage lung cancer (ESLC) and severe comorbidities, the cost-effectiveness of early intervention may be reduced by screening and treatment-related morbidity and mortality in addition to the risk for non-cancer-related deaths.OBJECTIVES: The use of bronchoscopic treatment (BT) for centrally located ESLC as minimally invasive technique has raised questions whether this approach will be more cost-effective than standard surgical resection in the above-mentioned cohort of patients.METHODS: The cost-effectiveness of BT of 32 medically inoperable patients with intraluminal tumor has been compared to a matched control group of surgically treated stage IA cancer patients.RESULTS: Median follow-up after BT for ESLC has been 5 years (range 2-10) versus 6.7 years (range 2-10) for the surgical group. Five patients (16%) developed subsequent primaries/local recurrences after BT versus 4 (12.5%) in the surgical group. The respective percentages of actual survival during follow-up have been 50 and 41%, non-lung-cancer-related death 22 and 31% and lung-cancer-related death 28% in both groups, respectively. So far, the average costs per individual for early management by BT have been Euro 22,638 by surgery, and total expenses have been Euro 209,492 and Euro 724,403, respectively.CONCLUSIONS: Despite the worse initial health status of patients treated with BT, actual survival rates and costs for early intervention underscore the superior cost-effectiveness of BT as early intervention in properly selected individuals with ESLC in the central airways.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results